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The accuracy of the MicroScan WalkAway, BD Phoenix, and Vitek-2 systems for susceptibility testing of
quinolones and aminoglycosides against 68 enterobacteria containing qnrB, qnrS, and/or aac(6)-Ib-cr was
evaluated using reference microdilution. Overall, one very major error (0.09%), 6 major errors (0.52%), and 45
minor errors (3.89%) were noted.
Previous reports indicate that automated systems for suscep-
tibility testing are reliable in detecting quinolone-resistant en-
terobacteria (4, 7, 9, 12), but there is very limited information
on the accuracy of these systems with organisms expressing
plasmid-mediated quinolone resistance (PMQR) mechanisms.
PMQR genes determine the low level of resistance to quino-
lones and may favor or complement the selection of additional
mechanisms (5, 6, 10). They code for Qnr proteins, the acetyl-
transferase Aac(6)-Ib-cr, or the efflux systems QepA and
OqxAB. Aac(6)-Ib-cr also confers resistance to tobramycin
and amikacin.
Detection of strains harboring PMQR mechanisms usually
depends on genotypic assays (often PCR amplification and
sequencing of these genes), as we currently lack reliable phe-
notypic methods to detect these organisms. Qnr proteins and
Aac(6)-Ib-cr seem to be the most relevant PMQR mecha-
nisms in Spain and other European countries, as the plasmid
locations of the oqxAB (present in the chromosomes of most
Klebsiella pneumoniae strains) and qepA genes have uncom-
monly been described in this geographical location. Also, most
enterobacteria with plasmid-mediated qnr genes contain qnrA,
qnrB, or qnrS alleles, while those with qnrD and qnrC still seem
to be exceptional.
A previous study had evaluated four clinical strains of K. pneu-
moniae and the corresponding Escherichia coli transconjugants
carrying the qnrA1 gene with four automated systems (11). In this
study, the performance of three automated instruments for sus-
ceptibility testing of quinolones and aminoglycosides against bac-
teria containing qnrB, qnrS, and/or aac(6)Ib-cr was evaluated.
We tested 68 clinical isolates (one per patient), collected at
two centers in northern (Hospital Universitario Marqués de
Valdecilla, Santander) and southern (Hospital Virgen Mac-
arena, Seville) Spain, as indicated in Table 1.
qnrB, qnrS, and acc(6)-Ib-cr were detected by multiplex
PCR and sequencing of the obtained amplicons, as described
elsewhere (1). In total, 47 isolates produced a qnr determinant
(7 qnrB-related alleles, 40 qnrS1-related alleles), and 26 pro-
duced acc(6)-Ib-cr, with 5 isolates producing both types of
genes.
Reference MIC values for the tested organisms were deter-
mined by a broth microdilution assay according to CLSI guide-
lines (2). The following antimicrobial agents and concentra-
tions (mg/liter) were tested: nalidixic acid (0.5 to 1,024),
ciprofloxacin (0.015 to 32), norfloxacin (0.015 to 32), levofloxa-
cin (0.015 to 32), gentamicin (0.06 to 128), tobramycin (0.06 to
128), and amikacin (0.06 to 128). E. coli ATCC 25922 and
Pseudomonas aeruginosa ATCC 27853 were used as control
strains.
The following systems and corresponding panels were tested:
BD Phoenix (BD Diagnostic Systems, Sparks, MD; panel
UNMIC/ID-62), MicroScan WalkAway (Siemens, West Sacra-
mento, CA; urine combo 37), and Vitek-2 (bioMérieux-Vitek,
Hazelwood, MO; AST-N058). The relevant antimicrobial
agents and concentrations (mg/liter) evaluable in the used pan-
els or cards were as follows: for UNMIC/ID-62, ciprofloxacin
(0.125 to 2), norfloxacin (2 to 8), gentamicin (2 to 8), tobra-
mycin (2 to 8), and amikacin (8 to 32); for urine combo 37,
nalidixic acid (4, 16), ciprofloxacin (0.12, 1, 2), norfloxacin (1,
4, 8), levofloxacin (0.25, 2, 4), gentamicin (4 to 8), tobramycin
(4 to 8), and amikacin (8 to 32); and for AST-N058, nalidixic
acid (2 to 32), ciprofloxacin (0.25 to 4), gentamicin (1 to 16),
tobramycin (4 to 8), and amikacin (8 to 32).
The MICs obtained with the reference method or with the
automated systems were translated into clinical categories
(susceptible, intermediate, or resistant) according to the inter-
pretive criteria of the CLSI (3). Percentages of agreement in
clinical categories were calculated. The following types of dis-
agreements were considered: very major errors (resistant by
the reference method but susceptible by the test method),
major errors (susceptible by the reference method but resistant
by the test method), and minor errors (susceptible or resistant
by either the reference or the test method but intermediate by
the other method). Essential agreement was defined as when
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the same MIC values (within 1 dilution) were obtained by the
automated systems and the reference method; in this case,
when both MICs determined with the automated panels and by
reference microdilution were under or over the limit concen-
trations in the automated panels, these results were not con-
sidered to disagree.
The percentages of agreement in clinical categories and of
essential agreement and the number of errors made by the
automated methods, relative to the reference results obtained
by microdilution, are presented in Table 2.
The agreement in clinical categories was 90% for all com-
binations of agents and automated systems. Essential agree-
ment was also 90% in all except two cases (nalidixic acid and
ciprofloxacin results with MicroScan). In most cases where
essential agreement did not reach the highest theoretical value
of 100%, it was because the MICs obtained with the corre-
sponding system for the considered agent were 2 times
higher than the reference MIC, and only in a minority of cases
was this due to lower MICs obtained with the automated sys-
tem than with the reference method.
A total of 1,156 results (17 antibiotic/automated system com-
binations by 68 isolates) were obtained in this study, corre-
sponding to 476 for MicroScan, 340 for BD Phoenix, and 340
for Vitek-2. Overall, one very major error (0.09%; for nalidixic
acid and MicroScan), 6 major errors (0.52%; 2 for nalidixic
acid, 1 for ciprofloxacin, 2 for gentamicin, 1 for tobramycin),
and 45 minor errors (3.89%) were noted (Table 2). These
minor errors were evenly distributed between results for quin-
olones (4% of errors) and aminoglycosides (3.8%). When con-
sidering the three systems independently, the percentages of
errors presented small differences. Very major errors were
0.21% of the total number of results for MicroScan. Major
errors were 0.21% for MicroScan, 0.88% for BD Phoenix, and
0.59% for Vitek-2. Finally, minor errors were 3.57% for Mi-
croScan, 5.00% for BD Phoenix, and 2.06% for Vitek-2.
When specifically considering organisms producing Aac(6)-
Ib-cr, 5 minor errors were observed for tobramycin, including
3 with MicroScan and 2 with Vitek-2.
It has been recommended that the performance of suscep-
tibility tests is considered adequate when the total error rate is
10%, with 1.5% of errors being very major errors and
3.0% being major errors, and when the overall essential MIC
agreement is 90% (13). Taking these values as a reference,
the three systems that we have evaluated in this study
(MicroScan, BD Phoenix, and Vitek-2) can be considered re-
liable for susceptibility testing of quinolones and aminoglyco-
sides against enterobacteria with the qnrB, qnrS, and/or
aac(6)Ib-cr gene.
Because of the predefined number of wells available in the
panels or cards of these systems, only a limited number of
concentrations (sometimes corresponding to discontinuous
scales) of both quinolones and aminoglycosides can be tested,
which often precludes obtainment of concrete MIC values. In
the case of quinolones, it should be considered that PMQR
genes, by themselves, cause only low-level resistance; for this
reason, it would be convenient to increase the number of wells
TABLE 1. Enterobacteria isolates containing qnrB, qnrS, and/or
aac(6)-Ib-cr that were evaluated in this study
Species (no. of isolates) PMQR gene(s)expresseda
No. of
isolates
Escherichia coli (32) qnrB 1
qnrS1 9
aac(6)-Ib-cr 21
aac(6)-Ib-cr  qnrA1 1
Enterobacter cloacae (29) qnrB5 1
qnrB2 1
qnrS1 25
qnrS1  aac(6)-Ib-cr 2
Citrobacter freundii (2) qnrB 2
Klebsiella pneumoniae (2) qnrB 1
qnrS1 1
Klebsiella oxytoca (2) qnrS1 1
qnrS1  aac(6)-Ib-cr 1
Enterobacter aerogenes (1) qnrB 1
a The exact allele was not determined for the qnrB gene of some isolates
because of incomplete gene amplification.
TABLE 2. Summary of the results obtained with automated




















99 88 1 0 0
Vitek-2 (2, 4,
8, 16, 32)
97 93 0 2 0
Ciprofloxacin MicroScan
(0.12, 1, 2)








96 96 0 0 3
Norfloxacin MicroScan
(1, 4, 8)
96 90 0 0 3
BD Phoenix
(2, 4, 8)
96 100 0 0 3
Levofloxacin MicroScan
(0.25, 2, 4)
99 99 0 0 1
Gentamicin MicroScan
(4, 8)
93 97 0 1 4
BD Phoenix
(2, 4, 8)
91 97 0 1 5
Vitek-2 (1, 2,
4, 8, 16)
97 97 0 0 2
Tobramycin MicroScan
(4, 8)
90 99 0 0 7
BD Phoenix
(2, 4, 8)
94 97 0 1 3
Vitek-2
(4, 8)
97 99 0 0 2
Amikacin MicroScan
(8, 16, 32)
100 99 0 0 0
BD Phoenix
(8, 16, 32)
100 100 0 0 0
Vitek-2 (8,
16, 32)
100 91 0 0 0
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with low concentrations of these compounds. This will also
help in recognizing enterobacteria susceptible to nalidixic acid
and enterobacteria with decreased susceptibility to fluoro-
quinolones, a phenotype often associated with the presence of
PMQR genes in organisms lacking other mechanisms of quin-
olone resistance (6, 10). Similarly, including more wells with
low concentrations of quinolones would also be helpful in
presumptively recognizing strains overexpressing the AcrAB-
TolC efflux pump and presenting elevated MICs of nalidixic
acid in comparison to those of other quinolones (8).
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